Table 1 Baseline patient characteristics

Demographic

 Age

63.9 ± 19.3

66.5 ± 15.4

0.367

 Male gender

61.4% (n = 35)

68.9% (n = 91)

0.313

Clinical

 Body-mass index

24.8 ± 3.9

25.2 ± 3.7

0.548

 Mean sitting blood pressure-mmHg

  Systolic

134.9 ± 16.6

131.0 ± 14.0

0.123

  Diastolic

77.2 ± 10.8

77.4 ± 10.5

0.135

 Urine protein-to-creatinine ratio

1.84 (0.89 ∼ 2.77)

1.81 (0.84 ∼ 2.78)

0.723

 Estimated glomerular filtration rate ml/min/1.73 m2

50.9 ± 31.1

42.5 ± 19.9

0.062

 Hemoglobin (g/liter)

12.0 ± 1.9

11.8 ± 1.9

0.525

 Chronic kidney disease stage

0.173

  Stage I

10.5% (n = 6)

4.5% (n = 6)

  Stage II

17.5% (n = 10)

7.6% (n = 10)

  Stage IIIA

14.0% (n = 8)

23.5% (n = 31)

  Stage IIIB

28.1% (n = 16)

36.4% (n = 48)

  Stage IV

29.8% (n = 17)

28.0% (n = 37)

Etiology

0.917

 Hypertensive nephropathy

36.8% (n = 21)

34.1% (n = 45)

 Chronic glomerulonephritis

43.9% (n = 25)

47.0% (n = 62)

 Interstitial nephritis

19.3% (n = 11)

18.9% (n = 25)

 Triglycerides (mg/dl)

146.3 ± 100.2

133.0 ± 79.4

0.369

 Cholesterol (mg/dl)

  Total

198.9 ± 52.4

183.7 ± 45.7

0.062

 Low-density lipoprotein

116.4 ± 38.8

112.4 ± 37.7

0.567

 High-density lipoprotein

51.8 ± 14.0

48.6 ± 17.3

0.309

 Serum potassium (mmol/liter)

4.2 ± 0.5

4.4 ± 0.6

0.037

Antihypertensive drugs received at baseline

 Calcium-channel blocker

52.6% (n = 30)

43.9% (n = 58)

0.272

 Beta-blocker

21.1% (n = 12)

15.9% (n = 21)

0.393

 Diuretic

35.1% (n = 20)

47.0% (n = 62)

0.130

 Alpha-blocker

14.0% (n = 8)

5.3% (n = 7)

0.042